Fact CheckerSign in

NCT07427511Recruiting

SwissNeuroRehab - HDHI

SwissNeuroRehab - High Dose High Intensity Neurorehabilitation Along the Continuum of Care

Source: ClinicalTrials.gov · Last updated 10 Mar 2026

Brief summary (registry, in English)

High-dose, high-intensity (HDHI) neurorehabilitation has shown promise for improving functional outcomes after acquired brain injury (ABI), yet its feasibility and impact across different stages of care and real-world clinical settings remain insufficiently understood. The SwissNeuroRehab (SNR) initiative, bringing together Swiss rehabilitation centres to develop and evaluate innovative, technology-supported models of neurorehabilitation, provides the broader framework within which this study is conducted. Within this framework, a structured HDHI therapy pathway supported by CE-marked digital neurorehabilitation tools has been developed for delivery across inpatient, outpatient, and home environments in Switzerland. This multicentre, non-randomised interventional feasibility study evaluates the feasibility and preliminary clinical effects of implementing this HDHI rehabilitation pathway for adults with stroke in subacute and chronic stages. Participants will receive approximately 300 minutes per week of active, technology-supported training in addition to standard rehabilitation care, following an individually tailored pathway across settings. Standardised clinical assessments, patient-reported outcomes, documentation of rehabilitation procedures, and socioeconomic measures will be collected at baseline, discharge, and follow-up timepoints up to 12-15 months post-enrollment. The primary aim of the study is to assess the feasibility of the HDHI intervention within routine rehabilitation workflows across multiple Swiss centres. Feasibility will be evaluated through (i) adherence to at least half of the weekly 300-minute Active Training Time target and (ii) patients' perceived feasibility and satisfaction with the program. Secondary aims are to explore preliminary clinical and functional changes, patient-reported outcomes, and quantify socioeconomic impacts through dedicated surveys and cost data. Findings from this study will (i) determine whether a structured HDHI rehabilitation pathway can be feasibly implemented across diverse clinical contexts, (ii) provide initial estimates of clinical and socioeconomic outcomes to support planning of future controlled trials.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
120 (estimated)
First submitted
22 Jan 2026
Start date
10 Feb 2026
Primary completion date
31 May 2028
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Diseases
Stroke
NCT number
NCT07427511

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 10 Feb 2026 to the primary completion date, 31 May 2028
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Severe cognitive impairment
  • Uncontrolled seizure disorder or epilepsy - clinician's judgement)
  • Any medical condition that would compromise their safety (inability to communicate, vision or hearing impairment, heart condition that limits participation in exercise) and tolerability (cardiac contraindications)
  • Severe memory disorder

Other

  • Pain that would limit rehabilitation dose
  • Severe apraxia
  • Severe hemispatial neglect
  • Plegia of the affected limb

Who the study is looking for

  • Adults aged 18-85 years.
  • Confirmed diagnosis of stroke (ischemic or hemorrhagic) \>7 days ago
  • Be able to sit unassisted
  • Able and willing to give informed consent
  • Have motor difficulties of the Upper Extremity and/or Lower Extremity
  • Willing to commit to program length \& daily training dose
  • Willing to have assessments at start and end of program
  • Signed informed consent

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre Hospitalier Universitaire Vaudois
Coordinator of this site? Confirm its status
LausanneSwitzerlandRecruiting
Swiss Réhabilitation Sàrl
Coordinator of this site? Confirm its status
SullensSwitzerlandRecruiting
Klinik Valens
Coordinator of this site? Confirm its status
ValensSwitzerlandRecruiting
Lake Lucerne Institute
Coordinator of this site? Confirm its status
VitznauSwitzerlandNot yet recruiting
UniversitatSpital Zurich
Coordinator of this site? Confirm its status
ZurichSwitzerlandNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.